Orlistat PD Endpoint BE study [Regulatives / Guidelines]

posted by NK – India, 2024-04-30 06:33 (20 d 23:23 ago) – Posting: # 23966
Views: 324

Dear All,

As per the USFDA recommendation, if we conduct the Orlistat PD Endpoint BE study, we may have data (fecal fat) for Baseline, Test, Ref1 and Ref2

Can anyone explain how to analyze the pharmacodynamic study data step by step? how to establish dose response relationship?. Any example dataset are available?

Kindly suggest, which software (WinNonlin/SAS/etc…) is required to analyze these data.


Complete thread:

UA Flag
 Admin contact
23,033 posts in 4,835 threads, 1,647 registered users;
35 visitors (0 registered, 35 guests [including 6 identified bots]).
Forum time: 05:57 CEST (Europe/Vienna)

Give me a fruitful error any time, full of seeds, bursting with its own corrections.
You can keep your sterile truth for yourself.    Vilfredo Pareto

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz